Arch Therapeutics (ARCH) Targets Hemostasis Division of Growing $52 Billion In-Vitro Diagnostics Market

NEW YORK, NY -- (Marketwired) -- 06/24/13 -- The following is an investment opinion highlighting Arch Therapeutics (OTCQB: ARTH), Neuralstem (NYSE: CUR), StemCells (NASDAQ: STEM) and Osiris Therapeutics (NASDAQ: OSIR). The current In-Vitro Diagnostics (IVD) market includes immunochemistry, molecular diagnostics, blood donor screening, hematology, hemostasis, and point-of-care testing. As per a new research report by RNCOS Industry Research Solutions, "In Vitro Diagnostic Market Analysis to 2017," IVD Industry represents one of the most lucrative segments in the global Healthcare Industry. The size of the global IVD market was in excess of $52 Billion in 2012 and is expected to rise at a CAGR of 7% through 2017. (http://beforeitsnews.com/healthcare/2013/04/ivd-market-to-cross-us-70-billion-by-2017-2446570.html)

As more companies like Neuralstem (NYSE: CUR), StemCells (NASDAQ: STEM) and Osiris Therapeutics (NASDAQ: OSIR) come online with products developed around biologic stem cell usage and natural occurring progenitor cells, the industries market fragmentation should begin to dissipate.

New comer Arch Therapeutics (OTCQB: ARTH), has recently unveiled its Hemostatic Agent; AC5™ to the world to rave reviews. AC5™ has seen dramatic improvement in hemostasis with animal testing. Hemostasis occurred over 30 times faster than control use of saline and 10 times faster than the use of cauterization. AC5™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision. Because it is not sticky or glue-like, it is ideal for use in the laparoscopic setting -- a challenge for much of the competition. Furthermore, it is transparent, enabling a surgeon to operate through it in order to prophylactically stop bleeding as it starts. Importantly, time to hemostasis for AC5™ is typically measured in seconds, rather than the many minutes of the much of the competition. In preclinical tests, AC5™ has been simple, effective, and versatile. For more information on Arch Therapeutics, please visit www.archtherapeutics.com.

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Century Capital Markets one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. No representation, expressed or implied, is made as to the accuracy, completeness or correctness. We accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.